Search

Search Constraints

You searched for: Author/Creator Putterman, Chaim

Search Results

1. 1107 Immune cell heterogeneity in lupus nephritis kidneys and its relation to histopathological features: lessons from the accelerating medicines partnership (AMP) in SLE Consortium. (14th December 2022)

2. 1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms. (14th December 2022)

3. 237 Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus. (April 2019)

4. 273 Safety of research cores obtained from clinically indicated biopsies in the accelerating medicines partnership network. (April 2019)

5. 300 Insights from single-cell RNA sequencing of skin and kidney in lupus nephritis. (April 2019)

7. A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort. Issue 6 (June 2014)

8. A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus. Issue 2 (4th February 2021)

9. Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Issue 2 (13th January 2020)